Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04741542 · ClinicalTrials.gov registry record · Phase 1
Safety of SP-420 in the Treatment of Transfusional Iron Overload
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04741542 is a Phase 1 study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 2 participants.
The verdict
NCT04741542, a Phase 1 study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420 may be better tolerated and safer than commercially available iron chelators. Iron chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is poor due to problems related to ease of administration, tolerability, and safety.
Interventions
- DRUG SP-420
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2024-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04741542
The ClinicalTrials.gov registry entry for NCT04741542 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SP-420 is the first listed.
NCT04741542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04741542 about?
NCT04741542 is a clinical study titled "Safety of SP-420 in the Treatment of Transfusional Iron Overload". This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420 may be better tolerated and safer than commercially available iron chelators. Iron chelation therapy (ICT) ...
What is the current status of trial NCT04741542?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-03-09. Estimated completion is 2024-01-10.
What interventions are being tested in trial NCT04741542?
The interventions under investigation include: SP-420 (DRUG).
Who is sponsoring clinical trial NCT04741542?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.